300039.SHE Shanghai Kaibao Pharmaceutical

300039.SHE trades 4.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

No fundamental analysis for Shanghai Kaibao Pharmaceutical yet.

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolv…

2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.

Shanghai Kaibao Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)

Dividend yield

2.77%

Forward dividend

0.13 CNY

Payout ratio

48.8%

Ex-dividend date

May 29, 2026

From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.

Last stock split: 13:10 on May 10, 2017.

Company name

Shanghai Kaibao Pharmaceutical

Ticker

300039.SHE

ISIN

CNE100000JZ3

Exchange

Shenzhen Stock Exchange

Listed since

Jan 8, 2010

Sector

Healthcare

Industry

Pharmaceuticals

Employees

1,197

Fiscal year end

December

Address

No. 88 Chengpu Road, Shanghai, China, 201401

Phone

86 21 3757 2030

Website

xykb.com

About Shanghai Kaibao Pharmaceutical

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules to promote blood circulation and unblocks meridians; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.

• Mr. Yingbin ZhouGM & Director · born 1978
• Mr. You Long ChenFinancial Director · born 1975
• Mr. Jianzhong LiuDeputy GM & Non-Independent Director · born 1973
• Mr. Liwang RenBoard Secretary & Non-Independent Director · born 1970
• Mr. Ying Jun ZhuDeputy General Manager · born 1970
• Ya Ru LiAccounting Supervisor